Brokerages predict that Neogen Co. (NASDAQ:NEOG) will report $0.24 earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for Neogen’s earnings, with the highest EPS estimate coming in at $0.25 and the lowest estimate coming in at $0.23. Neogen reported earnings per share of $0.20 in the same quarter last year, which would suggest a positive year-over-year growth rate of 20%. The firm is scheduled to announce its next earnings report on Tuesday, March 20th.

On average, analysts expect that Neogen will report full-year earnings of $1.06 per share for the current financial year, with EPS estimates ranging from $0.95 to $1.11. For the next year, analysts forecast that the company will post earnings of $1.16 per share, with EPS estimates ranging from $1.07 to $1.27. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Neogen.

Neogen (NASDAQ:NEOG) last issued its earnings results on Wednesday, January 3rd. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.07. Neogen had a return on equity of 10.72% and a net margin of 13.47%. The company had revenue of $101.80 million for the quarter, compared to analyst estimates of $102.46 million. During the same period in the prior year, the firm posted $0.29 EPS. The business’s revenue was up 12.2% compared to the same quarter last year.

Several research analysts have weighed in on the company. Zacks Investment Research lowered Neogen from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Stephens reaffirmed a “hold” rating and issued a $62.00 target price on shares of Neogen in a research report on Wednesday. BidaskClub lowered Neogen from a “buy” rating to a “hold” rating in a research report on Thursday. Roth Capital set a $62.00 target price on Neogen and gave the stock a “hold” rating in a research report on Thursday, January 4th. Finally, Craig Hallum upped their price target on Neogen from $46.50 to $60.00 and gave the stock a “hold” rating in a research note on Thursday, December 7th. Five analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $63.25.

In other news, CFO Steven J. Quinlan sold 4,000 shares of the company’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $80.26, for a total transaction of $321,040.00. Following the completion of the sale, the chief financial officer now owns 14,103 shares in the company, valued at approximately $1,131,906.78. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Edward Bradley sold 17,824 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $80.32, for a total value of $1,431,623.68. Following the sale, the vice president now owns 27,212 shares of the company’s stock, valued at approximately $2,185,667.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,824 shares of company stock valued at $3,870,364. 4.20% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NEOG. Schwab Charles Investment Management Inc. boosted its stake in shares of Neogen by 3.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 158,981 shares of the company’s stock worth $10,988,000 after acquiring an additional 4,824 shares in the last quarter. First Trust Advisors LP boosted its stake in Neogen by 39.7% during the 2nd quarter. First Trust Advisors LP now owns 20,788 shares of the company’s stock valued at $1,437,000 after purchasing an additional 5,904 shares during the period. SG Americas Securities LLC bought a new stake in Neogen during the 2nd quarter valued at approximately $154,000. Victory Capital Management Inc. boosted its stake in Neogen by 17.5% during the 2nd quarter. Victory Capital Management Inc. now owns 2,989 shares of the company’s stock valued at $207,000 after purchasing an additional 446 shares during the period. Finally, Swiss National Bank boosted its stake in Neogen by 2.1% during the 2nd quarter. Swiss National Bank now owns 63,650 shares of the company’s stock valued at $4,399,000 after purchasing an additional 1,300 shares during the period. Institutional investors own 86.96% of the company’s stock.

Shares of Neogen (NASDAQ NEOG) traded down $0.08 during mid-day trading on Friday, reaching $59.12. The company’s stock had a trading volume of 155,989 shares, compared to its average volume of 172,271. Neogen has a 12 month low of $44.63 and a 12 month high of $64.42. The firm has a market cap of $3,050.14, a price-to-earnings ratio of 58.82, a P/E/G ratio of 3.73 and a beta of 1.54.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/analysts-anticipate-neogen-co-neog-to-post-0-24-earnings-per-share/1806092.html.

Neogen Company Profile

Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.

Get a free copy of the Zacks research report on Neogen (NEOG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.